SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Global Arena Holding, Inc. – ‘10-Q/A’ for 6/30/22

On:  Tuesday, 9/20/22, at 1:47pm ET   ·   For:  6/30/22   ·   Accession #:  1877104-22-8   ·   File #:  0-49819

Previous ‘10-Q’:  ‘10-Q’ on 8/22/22 for 6/30/22   ·   Next:  ‘10-Q’ on 11/21/22 for 9/30/22   ·   Latest:  ‘10-Q/A’ on 4/4/24 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/20/22  Global Arena Holding, Inc.        10-Q/A      6/30/22   58:6.3M                                   BioRegenx Inc.

Amendment to Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q/A      Gahc 10Q2Q22 Am1                                    HTML   1.27M 
 2: EX-31       Certification -- §302 - SOA'02 --                   HTML     20K 
                gahc10q2q22am1exhibit31                                          
 3: EX-32       Certification -- §906 - SOA'02 --                   HTML     17K 
                gahc10q2q22am1exhibit32                                          
 9: R1          Document and Entity Information                     HTML     69K 
10: R2          Condensed Consolidated Balance Sheets               HTML    100K 
11: R3          Condensed Consolidated Balance Sheets               HTML     39K 
                (Parenthetical)                                                  
12: R4          Condensed Consolidated Statements of Operations     HTML    112K 
                (Unaudited)                                                      
13: R5          Condensed Consolidated Statements of Stockholders'  HTML     81K 
                Deficit                                                          
14: R6          Condensed Consolidated Statements of Cash Flows     HTML     87K 
                (Unaudited)                                                      
15: R7          Organization                                        HTML     34K 
16: R8          Summary of Significant Accounting Policies          HTML    107K 
17: R9          Acquisition Deposits                                HTML     25K 
18: R10         Accrued Expenses                                    HTML     32K 
19: R11         Promissory Notes Payable                            HTML     21K 
20: R12         Convertible Promissory Notes Payable                HTML     54K 
21: R13         Derivative Financial Instruments                    HTML     43K 
22: R14         Stockholders' Deficit                               HTML    119K 
23: R15         Commitments and Contingencies                       HTML     24K 
24: R16         Agreements                                          HTML     46K 
25: R17         Subsequent Events                                   HTML     28K 
26: R18         Summary of Significant Accounting Policies          HTML    137K 
                (Policies)                                                       
27: R19         Summary of Significant Accounting Policies          HTML     79K 
                (Tables)                                                         
28: R20         Accrued Expenses (Tables)                           HTML     31K 
29: R21         Convertible Promissory Notes Payable (Tables)       HTML     50K 
30: R22         Derivative Financial Instruments (Tables)           HTML     44K 
31: R23         Stockholders' Deficit (Tables)                      HTML    111K 
32: R24         Organization (Narratives) (Details)                 HTML     95K 
33: R25         Summary of Significant Accounting Policies          HTML     28K 
                (Schedule Of Antidilutive Securities Excluded From               
                Earnings) (Details)                                              
34: R26         Summary of Significant Accounting Policies          HTML     32K 
                (Schedule Of Fair Value Of Assets And Liabilities)               
                (Details)                                                        
35: R27         Acquisition Deposits (Narratives) (Details)         HTML     82K 
36: R28         Accrued Expenses (Schedule of Accrued Liabilities)  HTML     26K 
                (Details)                                                        
37: R29         Promissory Notes Payable (Narratives) (Details)     HTML     41K 
38: R30         Convertible Promissory Notes Payable (Schedule Of   HTML     39K 
                Convertible Promissory Notes Payable) (Details)                  
39: R31         Convertible Promissory Notes Payable (Schedule Of   HTML     50K 
                Convertible Promissory Notes Payable) (Details)                  
                (Parenthetical)                                                  
40: R32         Convertible Promissory Notes Payable (Schedule Of   HTML     35K 
                Rollfoward Of Convertible Promissory Notes                       
                Payable) (Details)                                               
41: R33         Convertible Promissory Notes Payable (Narrative)    HTML     20K 
                (Details)                                                        
42: R34         Derivative Financial Instruments (Schedule Of       HTML     34K 
                Valuation Techniques Used In Fair Value Of                       
                Derivative Liability) (Details)                                  
43: R35         Derivative Financial Instruments (Schedule Of       HTML     27K 
                Changes In Fair Value Of Financial Derivatives)                  
                (Details)                                                        
44: R36         Stockholders' Deficit (Schedule Of Stock Option     HTML     51K 
                Activity) (Details)                                              
45: R37         Stockholders' Deficit (Schedule Of Exercise Price   HTML     26K 
                For Options Outstanding) (Details)                               
46: R38         Stockholders' Deficit (Schedule Of Warrant          HTML     55K 
                Activity) (Details)                                              
47: R39         Stockholders' Deficit (Schedule Of Exercise Price   HTML     74K 
                For Warrants Outstanding) (Details)                              
48: R40         Stockholders' Deficit (Series B Preferred Stock)    HTML     37K 
                (Narratives) (Details)                                           
49: R41         Stockholders' Deficit (Common Stock) (Narratives)   HTML     37K 
                (Details)                                                        
50: R42         Stockholders' Deficit (Warrant Activity)            HTML     36K 
                (Narratives) (Details)                                           
51: R43         Commitments and Contingencies (Narratives)          HTML     31K 
                (Details)                                                        
52: R44         Agreements (Narratives) (Details)                   HTML    200K 
53: R45         Subsequent Events (Narratives) (Details)            HTML     48K 
56: XML         IDEA XML File -- Filing Summary                      XML    106K 
54: XML         XBRL Instance -- gahc-20220630_htm                   XML   1.45M 
55: EXCEL       IDEA Workbook of Financial Reports                  XLSX    119K 
 4: EX-101.CAL  XBRL Calculations -- gahc-20220630_cal               XML     88K 
 5: EX-101.DEF  XBRL Taxonomy Extension Definitive Linkbase          XML    536K 
                Document -- gahc-20220630_def                                    
 6: EX-101.LAB  XBRL Labels -- gahc-20220630_lab                     XML   1.71M 
 7: EX-101.PRE  XBRL Presentations -- gahc-20220630_pre              XML    810K 
 8: EX-101.SCH  XBRL Schema -- gahc-20220630                         XSD    185K 
57: JSON        XBRL Instance as JSON Data -- MetaLinks              326±   487K 
58: ZIP         XBRL Zipped Folder -- 0001877104-22-000008-xbrl      Zip    241K 




        
Filing Submission 0001877104-22-000008 – SGML Text

Original SGML Text submitted by:  BioRegenx Inc.  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 12:00:14.2pm ET